Ga 68-DOTATATE PET/CT for the Localization of Phosphaturic Mesenchymal Tumors in Patients with Osteomalacia

This clinical trial evaluates how well a recent imaging technique, Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT), works in diagnosing osteomalacia. This imaging technique may be more sensitive to localize the source of the hormone, FGF23 which have caused the low phosphate levels and bone disease. in patients with osteomalacia. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this clinical research, Ga 68-DOTATATE. Because some cancers take up Ga 68-DOTATATE, it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. This study may help researchers determine if Ga 68-DOTATATE PET/CT is more sensitive to localize the source of the hormone in patients with osteomalacia.

Additional locations may be listed on ClinicalTrials.gov for NCT03736564.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase I/II

Trial Typediagnostic

Lead OrganizationMayo Clinic in Rochester

Principal InvestigatorMatthew Truman Drake

• Primary ID17-008120
• Secondary IDsNCI-2023-00775
• ClinicalTrials.gov IDNCT03736564